September 8, 2026
Defence Therapeutics Inc.
ISIN: CA24463V1013
Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
Montreal, QC, Canada, September 8, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics...
Read more >>Defence Therapeutics Expands Radiopharmaceutical Development Strategy With Alpha and Beta-Emitter Programs
Montreal, QC, Canada, August 31st, 2026 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the expansion of its radiopharmaceutical development program to evaluate alpha-emitting and...
Read more >Defence Therapeutics Strengthens Radiopharmaceutical Leadership With Appointment of Dr. Ryan Simms as Chief Operating Officer and Head of Radiopharmaceutical Programs
Montreal, QC, Canada, August 17, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Ryan Simms, PhD, as Chief Operating Officer (“COO”)...
Read more >Defence Therapeutics Appoints Dr. Amie Phinney as President and Chief Executive Officer
Montreal, QC, Canada, August 4, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, is pleased to announce the appointment of Dr. Amie Phinney, PhD, MBA, as the President...
Read more >Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform
Montreal, QC, Canada, July 8, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, today announced the opening of a new office at McMaster Innovation Park in Hamilton, Ontario,...
Read more >Defence Therapeutics to Participate in BIO International Convention 2026 Next Week for Strategic Partnership Discussions
Montreal, QC, Canada, June 17th, 2026 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce its participation in the BIO International Convention 2026, taking place June 22-25 in San Diego, California. Defence’s team...
Read more >Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to its Board of Directors
Montreal, QC, Canada, June 3rd, 2026 - Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Beaver to its Board of Directors. Dr. Beaver brings more than two...
Read more >Defence Therapeutics Appoints Antibody Drug Conjugates Pioneer Dr. John Lambert to its Board of Directors
Montreal, QC, Canada, June 1st, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the appointment of Dr. John Lambert to its Board of Directors, effective immediately. Dr. Lambert brings more...
Read more >Defence Therapeutics Enhances In-House ADC Development Platform with Expanded Analytical and Cellular Testing Capabilities
Montreal, QC, Canada, May 19th, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the expansion of internal capabilities to execute critical stages of its ACCUM®-enabled Antibody Drug Conjugates (“ADC”) development...
Read more >Defence Therapeutics Announces Closing of Private Placement of Units for Gross Proceeds of $9,595,000
Montreal, QC, Canada, March 9, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the closing of a private placement (the “Private Placement”) of 17,445,455 units (the “Units”) at a price...
Read more >Defence Therapeutics to Showcase Accum Platform at Key International Industry Events in March
Montreal, QC, Canada, March 2nd, 2026 -- Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum® platform, today outlined its participation in a series of major international industry events taking place in March 2026. These high-profile meetings will provide Defence with...
Read more >Defence Therapeutics Aligns Accum ADC Strategy through Multidisciplinary Scientific Advisory Board
Montreal, QC, Canada, February 10th, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology and precision intracellular drug-delivery company, reported on its Scientific Advisory Board (“SAB”) meeting held on January 30, 2026, focused on advancing the strategic positioning of Accum® for antibody–drug conjugate (“ADC”) applications. The discussion...
Read more >Defence Therapeutics to Present at the World ADC Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform
Montreal, QC, Canada, February 4th, 2026 – Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced that it will present at World ADC Europe 2026, taking place February 23–26, 2026, in London, UK. Defence will showcase its proprietary Accum® platform, a...
Read more >